Dermatology Consultation Service

The NIAMS Dermatology Consult Service (DCS) provides high-quality, complex medical dermatology consultation and management for patients evaluated under NIH clinical research protocols at the NIH Clinical Center.

The DCS serves as a central clinical resource for individuals with rare diseases that have cutaneous manifestations, as well as for patients experiencing dermatologic adverse reactions to investigational and experimental therapeutic agents.

Recognized for excellence in patient care—including the NIH Director’s Award for Exceptional Patient Care and NIH Clinical Center NP of the Year—the program reflects a sustained commitment to clinical distinction within the NIH intramural research environment.

The service also plays an important educational role. It provides training to Dermatology Branch clinical fellows, fellows from other NIH Institutes, and visiting dermatology residents from across the country. Complex and instructive cases evaluated by the DCS have been featured in NIH Grand Rounds and in the Journal of the American Academy of Dermatology.

In parallel with its clinical mission, the DCS contributes to high-impact clinical and translational research through interdisciplinary collaborations within and beyond the NIH Intramural Research Program.

The group has helped define and characterize rare and immune-mediated disorders, including ADA2 deficiency, DIRA, PLAID and SAVI syndromes, GATA2 syndrome, MAP2K1-associated melorheostosis, and cutaneous-skeletal hypophosphatemia syndrome—many of which have been described in high-impact publications.

The DCS has also provided critical clinical insight into dermatologic adverse reactions to targeted and immunomodulatory therapies, including anti-CTLA4 agents, VEGF inhibitors, sorafenib, voriconazole, daclizumab, cabozantinib, ibrutinib, and anakinra-associated amyloidosis.

Through expert clinical phenotyping, longitudinal management, and collaborative investigation, the DCS contributes to research involving interferonopathies, dyskeratosis congenita, VEXAS syndrome, tuberous sclerosis complex, Degos disease, and hereditary leiomyomatosis and renal cell cancer.

Collectively, these efforts underscore the DCS’s dual commitment to exceptional consultative care and to advancing translational discovery through multidisciplinary partnership.